001     177704
005     20240229133748.0
024 7 _ |a 10.1002/ijc.33885
|2 doi
024 7 _ |a pmid:34843121
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:117831944
|2 altmetric
037 _ _ |a DKFZ-2021-02752
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Stepien, Magdalena
|b 0
245 _ _ |a Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
260 _ _ |a Bognor Regis
|c 2022
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1645022659_8528
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Volume150, Issue8, 15 April 2022, Pages 1255-1268
520 _ _ |a Bile acids (BA) play different roles in cancer development. Some are carcinogenic and BA signaling is also involved in various metabolic, inflammatory, and immune-related processes. The liver is the primary site of BA synthesis. Liver dysfunction and microbiome compositional changes, such as during hepatocellular carcinoma (HCC) development, may modulate BA metabolism increasing concentration of carcinogenic BAs. Observations from prospective cohorts are sparse. We conducted a study (233 HCC case-control pairs) nested within a large observational prospective cohort with blood samples taken at recruitment when healthy with follow-up over time for later cancer development. A targeted metabolomics method was used to quantify 17 BAs (primary/secondary/tertiary; conjugated/un-conjugated) in pre-diagnostic plasma. Odd ratios (OR) for HCC risk associations were calculated by multivariable conditional logistic regression models. Positive HCC risk associations were observed for the molar sum of all BAs (ORdoubling  = 2.30, 95%CI = 1.76-3.00) and choline- and taurine-conjugated BAs. Relative concentrations of BAs showed positive HCC risk associations for glycoholic acid and most taurine-conjugated BAs. We observe an association between increased HCC risk and higher levels of major circulating BAs, from several years prior to tumor diagnosis and after multivariable adjustment for confounders and liver functionality. Increased in BA concentration is accompanied by a shift in BA profile towards higher proportions of taurine-conjugated BAs, indicating early alterations of BA metabolism with HCC development. Future studies are needed to assess BA profiles for improved stratification of patients at high HCC risk and to determine whether supplementation with certain BAs may ameliorate liver dysfunction. This article is protected by copyright. All rights reserved.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a bile acid metabolism
|2 Other
650 _ 7 |a biomarkers
|2 Other
650 _ 7 |a cancer prevention
|2 Other
650 _ 7 |a hepatocellular carcinoma
|2 Other
650 _ 7 |a obesity
|2 Other
700 1 _ |a Lopez-Nogueroles, Marina
|b 1
700 1 _ |a Lahoz, Agustin
|b 2
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 3
700 1 _ |a Perlemuter, Gabriel
|b 4
700 1 _ |a Voican, Cosmin
|b 5
700 1 _ |a Ciocan, Dragos
|b 6
700 1 _ |a Boutron-Ruault, Marie-Christine
|0 0000-0002-5956-5693
|b 7
700 1 _ |a Jansen, Eugene
|b 8
700 1 _ |a Viallon, Vivian
|b 9
700 1 _ |a Leitzmann, Michael
|b 10
700 1 _ |a Tjønneland, Anne
|b 11
700 1 _ |a Severi, Gianluca
|b 12
700 1 _ |a Mancini, Francesca Romana
|0 0000-0003-2297-3869
|b 13
700 1 _ |a Dong, Catherine
|b 14
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 15
|u dkfz
700 1 _ |a Fortner, Renee Turzanski
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 16
|u dkfz
700 1 _ |a Bergmann, Manuela M
|b 17
700 1 _ |a Boeing, Heiner
|b 18
700 1 _ |a Trichopoulou, Antonia
|b 19
700 1 _ |a Karakatsani, Anna
|b 20
700 1 _ |a Peppa, Eleni
|b 21
700 1 _ |a Palli, Domenico
|b 22
700 1 _ |a Krogh, Vittorio
|0 0000-0003-0122-8624
|b 23
700 1 _ |a Tumino, Rosario
|b 24
700 1 _ |a Sacerdote, Carlotta
|0 0000-0002-8008-5096
|b 25
700 1 _ |a Panico, Salvatore
|b 26
700 1 _ |a Bueno-de-Mesquita, H Bas
|b 27
700 1 _ |a Skeie, Guri
|b 28
700 1 _ |a Merino, Susana
|b 29
700 1 _ |a Ros, Raul Zamora
|0 0000-0002-6236-6804
|b 30
700 1 _ |a Sánchez, Maria Jose
|b 31
700 1 _ |a Amiano, Pilar
|b 32
700 1 _ |a Huerta, Jose Mª
|b 33
700 1 _ |a Barricarte, Aurelio
|b 34
700 1 _ |a Sjöberg, Klas
|b 35
700 1 _ |a Ohlsson, Bodil
|b 36
700 1 _ |a Nyström, Hanna
|b 37
700 1 _ |a Werner, Marten
|b 38
700 1 _ |a Perez-Cornago, Aurora
|b 39
700 1 _ |a Schmidt, Julie A
|0 0000-0002-7733-8750
|b 40
700 1 _ |a Freisling, Heinz
|0 0000-0001-8648-4998
|b 41
700 1 _ |a Scalbert, Augustin
|b 42
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 43
700 1 _ |a Christakoudi, Sofia
|0 0000-0001-9219-4436
|b 44
700 1 _ |a Gunter, Marc J
|b 45
700 1 _ |a Jenab, Mazda
|0 0000-0002-0573-1852
|b 46
773 _ _ |a 10.1002/ijc.33885
|g p. ijc.33885
|0 PERI:(DE-600)1474822-8
|n 8
|p 1255-1268
|t International journal of cancer
|v 150
|y 2022
|x 0020-7136
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177704
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-02-04
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-25
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2021
|d 2022-11-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2021
|d 2022-11-25
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21